Joel B. Braunstein, M.D., M.B.A.

Co-Founder, President and CEO

Dr. Braunstein is a board-certified cardiologist and internist, and has been CEO of C2N Diagnostics since its inception. Dr. Braunstein has co-founded and played a senior executive role in numerous emerging life sciences companies. He is a Founder and Managing Director of LifeTech Research (LTR) since 2004. Beside C2N and LTR, he currently serves as a corporate director at Tivorsan Pharmaceuticals, Centegen, Correx, NexGen Medical Systems, and 3PrimeDx. Dr. Braunstein received his M.D. with highest distinction from Northwestern University Medical School in 1996. Subsequently, he trained in internal medicine at the Brigham and Women’s Hospital, Harvard Medical School until 1999, and as a Fellow in Cardiovascular Medicine and Robert Wood Johnson National Clinical Scholar at the Johns Hopkins Medical Institutions. Additionally, he completed an M.B.A. with management focus in 2004 and maintained an Assistant Professor cardiology faculty position at Johns Hopkins University. He remains an advisor to the Johns Hopkins Carey School of Business and serves on the Commercial Advisory Board for University of Maryland Ventures. In 2010, he was named a Distinguished Alumnus of Johns Hopkins University.

Micah Onixt, J.D., M.B.A.

Company Secretary

Mr. Onixt is currently General Counsel and a Managing Director of LTR. Through LTR, he brings to C2N approximately 15 years of life sciences work experience. He was part of the team that helped to form C2N and to transfer the SILK-related intellectual property out of WU. Most recently, he was a partner in the Chicago office at DLA Piper LLP US and a recipient of the “40 Illinois Attorneys Under 40 to Watch” award from the Law Bulletin Publishing Company. During his 12 year tenure at DLA Piper, his practice consisted of representing both institutional investment funds, and private and public life sciences companies in the areas of corporate securities, technology transfer (product licensing, M&A), and intellectual property management. He has negotiated many partnerships; and drafted and prosecuted patents, copyrights, and trade secrets within the biotechnology, pharmaceutical and medical device spaces. Mr. Onixt is a current member of the American Bar Association and the American Intellectual Property Law Association. He maintains an adjunct professorship in technology transactions at the Loyola University Chicago School of Law. Mr. Onixt received his M.B.A. from the Northwestern University Kellogg School of Management in 2007, J.D. from Loyola University in 1998, and two bachelor’s degrees from the University of Michigan (English, ‘94) and University of Illinois at Chicago (Cellular Biology, ‘95). He is currently completing his M.S. in Molecular and Cellular Biology from the Illinois Institute of Technology.

Kevin Yarasheski, PhD

Senior Vice President

 

 

Tim West, Ph.D.

VP, Research and Development

Dr. West obtained his Ph.D. in molecular cell biology and neuroscience from Washington University. He conducted his graduate thesis research and post-doctoral training in the laboratory of Dr. David Holtzman, one of C2N’s scientific founders. In those capacities, Dr. West led a group of scientists and technicians studying neonatal stroke and hypoxic-ischemic injury. During 2006 and 2007, he served as Staff Scientist and Assistant Director of Technology Development for the Hope Center for Neurological Disorders at the Washington University School of Medicine. Dr. West has extensive experience in database management and computer programming, and supports C2N’s establishment of a software platform tracking work flow and inventories, stores data, and enhances quality control. Dr. West was a recipient of a Kauffman Fellowship for Bio-Entrepreneurship. He received his B.Sc. Honors in Molecular Biology at University College London and performed a laboratory internship at the Ludwig Institute for Cancer Research.

Ilana Fogelman, M.D., M.P.H.

VP, Regulatory and Clinical Affairs

Dr. Fogelman co-founded LTR with Dr. Braunstein in 2004 and through LTR was involved in the formation of C2N Diagnostics. She specializes in corporate and product pipeline valuation, drug development, clinical trial design and analysis, and FDA regulations. Dr. Fogelman is an expert in regulatory strategies and risk, and interpreting FDA actions, decisions, and requirements. From 1999 to 2003, Dr. Fogelman worked as a biotechnology analyst for Merrill Lynch and Salomon Smith Barney, covering small- to mid-cap public companies. From 1993 to 1999, Dr. Fogelman worked as a medical reviewer for FDA’s Center for Biologics Evaluation and Research, focusing on new products for infectious diseases, autoimmune and inflammatory disorders. In that position, she reviewed more than 80 INDs, 2 BLAs, and 2 BLA supplements for a variety of technologies, including monoclonal antibodies, cytokines, immunomodulators, cell and gene therapies, and vaccine therapies. While at the FDA, Dr. Fogelman was also the Principal Investigator of an HIV clinical trial, which she designed and implemented in collaboration with the NIH to evaluate the immunologic reconstitution of HIV-infected patients receiving highly active antiretroviral therapies. Dr. Fogelman obtained her M.D. from the University of São Paulo (Brazil) and a Master in Public Health from Harvard University. At Harvard, she also completed two postdoctoral research fellowships in HIV clinical trials and immunology.

Yan Helen Hu, Ph.D.

Director of Immunoassays

Dr. Hu is a molecular biologist who brings to C2N unique expertise in assay development, antibody therapeutics discovery and development. Dr. Hu obtained her PhD in molecular Genetics from Washington University. Following graduation, she worked with Dr. David Holtzman, one of C2N’s scientific founders, under the Ruth L. Kirschstein postdoctoral fellowship. In that position, she assumed a comparative proteomics approach and discovered novel biomarkers for early stage Alzheimer’s Disease. Dr. Hu subsequently worked in the pre-clinical group at Genentech, Inc. She successfully led the anti-interleukin 17 program (for autoimmune and inflammatory diseases) from late stage research to preclinical development and played a key role in preparation of an IND (Investigational New Drug) filing. At C2N, Dr. Hu leads the efforts in immunoassay development for preclinical and clinical testing of antibody therapeutics.

Philip Verghese, Ph.D.

Director, Research, Development, and Operations

Dr. Verghese is a protein and lipid biochemist with extensive experience in acute and chronic neurodegenerative disease models. He conducted his post-doctoral training in the laboratory of Dr. David Holtzman, one of C2N’s scientific founders, under the BrightFocus foundation postdoctoral research fellowship. His work on apolipoprotein E (apoE) (for Alzheimer’s disease) and nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1) (for acute neurodegeneration in the developing brain) has been published in high impact journals and added new perspectives in the field of neurodegeneration. Dr. Verghese’s graduate work was focused on peripheral lipid metabolism. He also holds a Graduate Diploma in Business Studies from Dublin Business School, Dublin, Ireland.

Erin Smith, B.S.

Laboratory and Quality Assurance Manager

Ms. Smith’s role at C2N includes supervision of the laboratory, shipping and quality assurance manager at C2N. Her role includes supervision of the laboratory, shipping and receiving, creation and revision of standard operating procedures, quality auditing, and document control. Prior to joining C2N, Ms. Smith spent over a decade co-managing a small animal imaging facility conducting collaborative research with investigators at Washington University School of Medicine.